KPIs & Operating Metrics(New)

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NovoCure (NVCR) Long-Term Debt Issuances (2014 - 2025)

NovoCure recorded quarterly Long-Term Debt Issuances of $100.0 million in Q3 2025, up 3.15% quarter-over-quarter from $96.9 million in Q2 2024.

NovoCure's Long-Term Debt Issuances history runs 8 years deep, the most recent figure standing at $100.0 million for Q3 2025.

In Q3 2025, Long-Term Debt Issuances changed N/A year-over-year to $100.0 million; the TTM figure through Mar 2026 stood at $100.0 million (up 3.15% YoY), while the FY2025 annual figure was $100.0 million, up 3.15% from the prior year.
Long-Term Debt Issuances came in at $100.0 million for Q3 2025 at NovoCure, up from $96.9 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $100.0 million in Q3 2025 to a low of $96.9 million in Q2 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	19.86 Bn
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	-
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	-
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	-
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	11.71 Mn
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	1.15 Bn
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	-
10	NovoCure	1.90 Bn	1.47 Bn	135.13 Mn	-

Historic Data

Download Data 🔒

Date	Value
Sep 30, 2025	99.98 Mn
Sep 30, 2025	99.98 Mn
Jun 30, 2024	96.92 Mn
Jun 30, 2024	96.92 Mn
Dec 31, 2020	558.44 Mn
Dec 31, 2020	558.44 Mn
Mar 31, 2018	149.15 Mn
Mar 31, 2018	149.15 Mn
Jun 30, 2017	19,000.00
Jun 30, 2017	19,000.00
Sep 30, 2016	72.87 Mn
Sep 30, 2016	72.87 Mn
Jun 30, 2016	17,000.00
Jun 30, 2016	17,000.00
Jun 30, 2015	-920,000.00
Jun 30, 2015	-920,000.00
Mar 31, 2015	23.81 Mn
Mar 31, 2015	23.81 Mn
Dec 31, 2014	54,000.00
Dec 31, 2014	54,000.00